In a head-to-head test of 50 breast cancer patients, ectoin 7% cream performed better than dexpanthenol 5% cream at preventing radiation burn severity. Ectoin users experienced noticeably less pain and itching by week 2, and reported better quality of life overall. Both creams successfully prevented the worst cases of radiation damage, but ectoin came out ahead.

Researchers split 50 patients into two groups—one using ectoin cream, one using dexpanthenol—twice daily during and two weeks after radiation therapy. They tracked radiodermatitis severity, symptoms, and skin-related quality of life weekly in a double-blind study (meaning neither patients nor researchers knew who got what).

Funding not disclosed in abstract